Perspective Therapeutics’ (CATX) “Buy” Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $14.00 price target on the stock.

Several other equities analysts also recently weighed in on CATX. HC Wainwright raised their price target on Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Truist Financial began coverage on Perspective Therapeutics in a research report on Monday, November 24th. They issued a “buy” rating and a $12.00 price objective on the stock. Piper Sandler began coverage on Perspective Therapeutics in a research note on Thursday, February 19th. They set an “overweight” rating and a $16.00 price objective on the stock. UBS Group reiterated a “buy” rating and set a $7.00 price objective (down from $18.00) on shares of Perspective Therapeutics in a research report on Friday, November 21st. Finally, Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Friday, January 30th. One research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $12.50.

Perspective Therapeutics Stock Down 5.3%

CATX stock opened at $4.60 on Tuesday. The company has a current ratio of 5.17, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01. The company’s 50 day simple moving average is $4.34 and its 200-day simple moving average is $3.44. Perspective Therapeutics has a 12 month low of $1.60 and a 12 month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings data on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.The company had revenue of $0.04 million for the quarter. On average, sell-side analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Perspective Therapeutics during the fourth quarter worth $84,000. XTX Topco Ltd increased its stake in Perspective Therapeutics by 36.5% in the fourth quarter. XTX Topco Ltd now owns 82,476 shares of the company’s stock valued at $227,000 after purchasing an additional 22,074 shares during the last quarter. nVerses Capital LLC purchased a new position in Perspective Therapeutics during the fourth quarter worth about $31,000. Opaleye Management Inc. purchased a new position in Perspective Therapeutics during the fourth quarter worth about $3,257,000. Finally, Engineers Gate Manager LP acquired a new stake in Perspective Therapeutics in the 4th quarter worth about $35,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

More Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Several major firms raised ratings or price targets, which supports upside sentiment: B. Riley raised its price target to $13 and kept a Buy rating (large implied upside). UBS increased its target to $8 with a Buy. Wedbush reaffirmed an Outperform and a $11 target. Article Title
• Positive Sentiment: BTIG issued a Buy rating, adding to the cluster of bullish research that can attract momentum investors and buyers ahead of earnings. Article Title
• Positive Sentiment: Brookline Capital Markets (analyst K. Dolliver) raised EPS forecasts across Q1–Q4 2026 and lifted FY2026 from ($1.98) to ($1.27) — a meaningful reduction in projected losses vs their prior view. Incremental beat/less-bad guidance in analyst models tends to be supportive for the stock. Note Brookline’s FY view still implies a loss below consensus. Article Title
• Neutral Sentiment: Perspective announced a quarterly earnings release date (upcoming). Earnings will likely be the primary near-term catalyst and could swing the stock either way depending on clinical/program updates, cash burn, or guidance. Article Title
• Negative Sentiment: Royal Bank of Canada lowered expectations for CATX’s stock price, which may pressure sentiment among investors who follow bank research or use RBC’s view for risk management. Article Title

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.